Global Health Action,
Год журнала:
2025,
Номер
18(1)
Опубликована: Май 30, 2025
Evidence
on
long
COVID
remains
limited
in
sub-Saharan
countries.
This
study
explored
the
occurrence
of
COVID-19-related
symptoms
and
factors
affecting
recovery
severity
Nairobi,
Kenya.
A
prospective
cohort
individuals
testing
positive
for
SARS-CoV-2
between
February
2022
2023
was
followed
until
June
2023.
were
assessed
every
three
months.
Time
to
analyzed
using
survival
analysis,
while
Cox
proportional
hazard
Poisson
regression,
respectively.
Among
291
participants
(median
age
34,
59.1%
female),
42
(14%)
had
severe/critical
infection.
At
6
12
months
post-positive
PCR,
53.1%
33.5%
≥
1
symptoms,
Fatigue
(40.2%),
pain
(36.8%),
sore
throat
headaches
(36.4%),
loss
strength
(31.6%)
most
common.
Median
time
longer
cases
than
mild/moderate
(234
vs
206
days,
p
=
0.016).
Participants
aged
40-64
years
experienced
slower
those
<
40
(aHR
0.635
[95%CI,
0.429;0.941]).
with
tertiary
education
recovered
faster
primary
1.869
1.050;3.327]).
Long
associated
female
sex
(aIRR
1.418
[95%CI;
1.078;1.864]),
(aIRR,
0.489
0.415;0.576]),
comorbidity
2.415
1.639;3.559]).
Six
post-infection,
half
lingering
a
third
still
affected
after
year.
Recovery
younger,
educated
individuals,
severe
more
common
women,
low
pre-existing
conditions.
The
burden
Kenya
requires
support
vulnerable
groups.
BMJ,
Год журнала:
2023,
Номер
unknown, С. e076990 - e076990
Опубликована: Ноя. 22, 2023
Abstract
Objective
To
investigate
the
effectiveness
of
primary
covid-19
vaccination
(first
two
doses
and
first
booster
dose
within
recommended
schedule)
against
post-covid-19
condition
(PCC).
Design
Population
based
cohort
study.
Setting
Swedish
Covid-19
Investigation
for
Future
Insights—a
Epidemiology
Approach
using
Register
Linkage
(SCIFI-PEARL)
project,
a
register
study
in
Sweden.
Participants
All
adults
(≥18
years)
with
registered
between
27
December
2020
9
February
2022
(n=589
722)
largest
regions
Individuals
were
followed
from
infection
until
death,
emigration,
vaccination,
reinfection,
PCC
diagnosis
(ICD-10
code
U09.9),
or
end
follow-up
(30
November
2022),
whichever
came
first.
who
had
received
at
least
one
vaccine
before
considered
vaccinated.
Main
outcome
measure
The
was
clinical
PCC.
Vaccine
estimated
Cox
regressions
adjusted
age,
sex,
comorbidities
(diabetes
cardiovascular,
respiratory,
psychiatric
disease),
number
healthcare
contacts
during
2019,
socioeconomic
factors,
dominant
virus
variant
time
infection.
Results
Of
299
692
vaccinated
individuals
covid-19,
1201
(0.4%)
follow-up,
compared
4118
(1.4%)
290
030
unvaccinated
individuals.
any
associated
reduced
risk
(adjusted
hazard
ratio
0.42,
95%
confidence
interval
0.38
to
0.46),
58%.
individuals,
21
111
only,
205
650
doses,
72
931
three
more
doses.
dose,
21%,
59%,
73%,
respectively.
Conclusions
results
this
suggest
strong
association
receiving
findings
highlight
importance
reduce
population
burden
Antimicrobial Stewardship & Healthcare Epidemiology,
Год журнала:
2023,
Номер
3(1)
Опубликована: Янв. 1, 2023
We
performed
a
systematic
literature
review
and
meta-analysis
on
the
effectiveness
of
coronavirus
disease
2019
(COVID-19)
vaccination
against
post-COVID
conditions
(long
COVID)
among
fully
vaccinated
individuals.Systematic
review/meta-analysis.We
searched
PubMed,
Cumulative
Index
to
Nursing
Allied
Health,
EMBASE,
Cochrane
Central
Register
Controlled
Trials,
Scopus,
Web
Science
from
December
1,
2019,
June
2,
2023,
for
studies
evaluating
COVID-19
vaccine
(VE)
individuals
who
received
two
doses
vaccine.
A
condition
was
defined
as
any
symptom
that
present
four
or
more
weeks
after
infection.
calculated
pooled
diagnostic
odds
ratio
(DOR)
(95%
confidence
interval)
between
unvaccinated
individuals.
Vaccine
estimated
100%
x
(1-DOR).Thirty-two
with
775,931
evaluated
effect
conditions,
which,
twenty-four
were
included
in
meta-analysis.
The
DOR
0.680
CI:
0.523-0.885)
an
VE
32.0%
(11.5%-47.7%).
36.9%
(23.1%-48.2%)
those
before
infection
68.7%
(64.7%-72.2%)
three
stratified
analysis
demonstrated
no
protection
infection.Receiving
complete
prior
contracting
virus
resulted
significant
reduction
throughout
study
period,
including
during
Omicron
era.
increase
when
supplementary
administered.
Journal of Medical Virology,
Год журнала:
2023,
Номер
95(6)
Опубликована: Июнь 1, 2023
Abstract
Long
COVID
has
been
reported
among
patients
with
COVID‐19,
but
little
is
known
about
the
prevalence
and
risk
factors
associated
long
6–12
months
after
infection
Omicron
variant.
This
a
large‐scale
retrospective
study.
A
total
of
6242
out
12
950
nonhospitalized
subjects
all
ages
SARS‐CoV‐2
(confirmed
by
polymerase
chain
reaction/rapid
antigen
test)
during
dominant
outbreak
(December
31,
2021–May
6,
2022)
in
Hong
Kong
were
included.
Prevalence
COVID,
frequencies
symptoms,
analyzed.
Three
thousand
four
hundred
thirty
(55.0%)
at
least
one
symptom.
The
most
symptom
was
fatigue
(1241,
36.2%).
Female
gender,
middle
age,
obesity,
comorbidities,
vaccination
infection,
having
more
presenting
fatigue/chest
tightness/headache/diarrhea
acute
stage
illness
identified
as
for
COVID.
Patients
who
had
received
three
or
doses
vaccine
not
lower
(adjusted
odds
ratio
1.105,
95%
confidence
interval
0.985–1.239,
p
=
0.088).
Among
vaccine,
there
no
significant
difference
between
CoronaVac
BNT162b2
(
>
0.05).
can
lead
to
proportion
infection.
Further
investigation
needed
uncover
mechanisms
underlying
development
determine
impact
various
such
vaccines.
Scientific Reports,
Год журнала:
2023,
Номер
13(1)
Опубликована: Дек. 6, 2023
Abstract
Long
COVID,
also
known
as
“post-acute
sequelae
of
COVID-19,”
affects
at
least
65
million
individuals
worldwide
with
a
wide
spectrum
symptoms
that
may
last
weeks,
months,
or
permanently.
Its
epidemiology
and
burden
in
Africa
are
unclear.
This
meta-analysis
examines
long-term
COVID-19
effects
the
WHO
African
Region.
A
systematic
search
several
databases
was
carried
out
up
to
12
February
2023
including
observational
studies
from
countries
reporting
cumulative
incidence
long
COVID
signs
symptoms.
Only
conducted
were
included.
Several
sensitivity
meta-regression
analyses
performed.
Among
1547
papers
initially
screened,
25
included,
consisting
29,213
participants.
The
any
symptomatology
48.6%
(95%
CI
37.4–59.8)
psychiatric
conditions
most
frequent,
particularly
post-traumatic
stress
disorder
reaching
25%
21.1–30.4).
Higher
age
(
p
=
0.027)
hospitalization
0.05)
associated
higher
frequency
COVID.
poses
significant
Africa,
concerning
conditions.
study
recommends
identifying
at-risk
people
defining
treatment
strategies
recommendations
for
long-COVID
patients.
High-quality
addressing
this
condition
setting
urgently
needed.
International Journal of Environmental Research and Public Health,
Год журнала:
2024,
Номер
21(3), С. 325 - 325
Опубликована: Март 11, 2024
The
COVID-19
pandemic
has
resulted
in
a
growing
number
of
patients
experiencing
persistent
symptoms
and
physiological
changes
after
recovering
from
acute
SARS-CoV-2
infection,
known
as
Long
COVID.
COVID
is
characterized
by
recurring
inflammation
across
multiple
organ
systems.
Diagnosis
can
be
challenging,
influenced
factors
like
demographics,
comorbidities,
immune
responses.
impacts
various
systems
have
neuropsychological
effects.
Health
disparities,
particularly
related
to
race,
contribute
higher
burden
infection
ongoing
minority
populations.
Managing
entails
addressing
spectrum
that
encompass
physical,
cognitive,
psychological
aspects.
recovery
period
for
with
vary
significantly,
the
severity
disease,
hospitalization,
age.
Currently,
there
are
no
universally
effective
treatments,
although
certain
interventions
show
promise,
necessitating
further
research.
Self-management
rehabilitation
programs
provide
relief,
but
more
research
needed
establish
their
effectiveness.
Preventive
measures
such
vaccination
use
antiviral
medications
metformin.
It
imperative
conduct
develop
evidence-based
guidelines
gain
better
understanding
long-term
implications
COVID-19.
could
substantial
economic
impact
on
labor
market,
productivity,
healthcare
expenditures,
overall
growth.
To
address
challenges
complications
face,
focus
strategies
promoting
telework
flexible
work
arrangements
accommodate
diverse
symptoms,
chronic
fatigue
other
In
conclusion,
this
review
emphasizes
multifaceted
complexity
need
its
potential
health
impacts.
Brain Communications,
Год журнала:
2024,
Номер
6(2)
Опубликована: Янв. 1, 2024
Abstract
Although
it
is
known
that
coronavirus
disease
2019
can
present
with
a
range
of
neurological
manifestations
and
in-hospital
complications,
sparse
data
exist
on
whether
these
initial
symptoms
are
closely
associated
post-acute
sequelae
SARS-CoV-2
(severe
acute
respiratory
syndrome
2;
PANSC)
female
versus
male
sex
impacts
symptom
resolution.
In
this
international,
multi-centre,
prospective,
observational
study
across
407
sites
from
15
countries
(30
January
2020
to
30
April
2022),
we
report
the
prevalence
risk
factors
PANSC
among
hospitalized
adults
investigate
differences
between
males
females
resolution
over
time.
included
altered
consciousness/confusion,
fatigue/malaise,
anosmia,
dysgeusia
muscle
ache/joint
pain,
which
information
was
collected
at
index
hospitalization
during
follow-up
assessments.
The
analysis
considered
time
individual
all
symptoms.
resulting
times
were
modelled
by
Weibull
regression,
assuming
mixed-case
interval
censoring,
age
as
covariates.
model
results
summarized
cumulative
probability
functions
age-adjusted
sex-adjusted
median
We
6862
2019,
who
had
participants
57
years
(39.2%
females).
Males
similar
baseline
characteristics,
except
more
(versus
females)
admitted
intensive
care
unit
(30.5
20.3%)
received
mechanical
ventilation
(17.2
11.8%).
Approximately
70%
patients
multiple
first
(median
=
102
days).
Fatigue
(49.9%)
myalgia/arthralgia
(45.2%)
most
prevalent
follow-up.
reported
in
generally
higher
males)
for
At
12
months,
anosmia
resolved
patients,
although
fatigue,
consciousness
myalgia
remained
unresolved
>10%
cohort.
Females
longer
(5.2
3.4
months)
those
than
one
symptom.
multivariable
analysis,
shorter
(hazard
ratio
1.53;
95%
confidence
1.39–1.69).
Intensive
admission
0.68;
0.60–0.77).
Post-discharge
stroke
uncommon
(0.3%
0.5%
males).
Despite
methodological
challenges
involved
collection
survey
data,
international
multi-centre
prospective
cohort
demonstrated
following
high.
Symptom
took
resolve
males.
This
supported
fact
while
sicker
illness,
disproportionately
affected
PANSC.
Frontiers in Public Health,
Год журнала:
2024,
Номер
12
Опубликована: Март 5, 2024
Introduction
A
substantial
proportion
of
the
over
700
million
COVID-19
cases
world-wide
experience
long-term
symptoms.
The
objectives
this
study
were
to
compare
symptom
trajectories
and
risk
factors
for
post-COVID-19
condition
after
Delta
Omicron
infection.
Methods
This
consecutively
recruited
patients
with
SARS-CoV-2
infection
from
November
2021
March
2022.
We
recorded
demographics,
comorbidities,
vaccination
status,
sick
leave,
18
symptoms
during
acute
4
months.
primary
outcome
measures
Secondary
work
school
absenteeism.
Results
followed
a
cohort
1,374
non-hospitalized
in
Bergen,
Norway,
at
three
time
points.
median
age
was
39.8
years
11%
children
<16
years.
Common
upper
respiratory
waned
follow-up.
Fatigue
remained
common
(40%)
until
months
(37%).
Four
post-infection,
reported
increased
frequencies
dyspnea
(from
15%
illness
25%
months,
p
<
0.001),
cognitive
9
32%,
0.001)
depression
1
17%,
0.001).
Patients
infected
less
(22%
versus
27%,
=
0.046)
smell/taste
problems
(5%
19%,
follow-up
than
those
Comorbidities
female
sex
persistent
Ten
percent
leave
illness,
reduced
absenteeism
(adjusted
ratio:
0.36,
95%
confidence
interval:
0.15,
0.72,
0.008).
Conclusion
At
home-isolated
overall
comparable
burden,
but
patients.
Several
It
is
worrying
that
dyspnea,
neurocognitive
symptoms,
particularly
depression,
significantly
first
Previous
protective
against
prolonged
leave.